CD8A and neoplasm: Beyond PD-L1, tumor mutation burden, cytotoxic CD8+ T cells/TILs, an “immunoscore”, T cell receptor clonality, immune gene signature/RNA repertoire, and major histocompatibility complex class polymorphisms are being investigated [18, 19].